Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 21 (July 20), 2008: pp. 3656
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2008.17.6016

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Google Scholar
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Mayer, E. L.
PubMed
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Mayer, E. L.
Related Articles
Right arrowRelated Correspondence

CORRESPONDENCE

In Reply

Harold J. Burstein, Erica L. Mayer

Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA

Drs Dang, Norton, and Hudis raise important questions about how much pilot or feasibility data should be required before widespread adoption of a new regimen or variant, especially in an evolving field like adjuvant trastuzumab-based therapy. Relevant considerations include the generalizability of the patient population and the assurances as to efficacy and safety. When appraising exploratory studies, point estimates of risk are probably less clinically significant than confidence intervals, given the small numbers of events and inherent patient selection factors. As we noted, trastuzumab effects may be so potent as to render the choice of specific chemotherapy regimens less material, and cardiac safety may be less of an issue if patients with higher ejection fractions, especially after anthracycline therapy, are treated. Nonetheless, the proven survival advantage and extensive safety experience reported among patients with HER-2–positive breast cancer receiving trastuzumab/chemotherapy in the published phase III trials informs our current preference for those treatment plans.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The author(s) indicated no potential conflicts of interest.


Related Correspondence

  • Dose-Dense Chemotherapy With Trastuzumab Is an Appropriate Option
    Chau Dang, Larry Norton, and Clifford Hudis
    JCO 2008 26: 3655-3656 [Full Text]



This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Google Scholar
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Mayer, E. L.
PubMed
Right arrow Articles by Burstein, H. J.
Right arrow Articles by Mayer, E. L.
Related Articles
Right arrowRelated Correspondence

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online